Positron emission tomography/magnetic resonance imaging evaluation of lung cancer: Current status and future prospects

Journal of Thoracic Imaging

Volumn 29, Issue 1, 2014, Pages 4-16

  Yoon, Soon Ho ^a,b   Goo, Jin Mo ^a,b   Lee, Sang Min ^a,b   Park, Chang Min ^a,b   Seo, Hyo Jung ^a   Cheon, Gi Jeong ^a  

^a Seoul National University   (South Korea)

^b Nuclear Medicine   (South Korea)

Author keywords

lung cancer; magnetic resonance imaging; positron emission tomography; positron emission tomography and computed tomography; review

Indexed keywords

ARTIFACT; BONE LESION; CANCER DIAGNOSIS; CANCER SIZE; CANCER STAGING; CLINICAL PRACTICE; COMPUTER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG DEVELOPMENT; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; LUNG BIOPSY; LUNG CANCER; LUNG NODULE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION EXPOSURE; RADIOLOGICAL PARAMETERS; RADIOLOGIST; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; THORACOTOMY; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE;

BONE NEOPLASMS; BRAIN NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SOFTWARE;

EID: 84891751712     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0000000000000062     Document Type: Review

References (81)

1. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379.
2. Wechalekar K, Sharma B, Cook G. PET/CT in oncology-a major advance. Clin Radiol. 2005;60:1143-1155.
3. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dualmodality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290:3199-3206.
4. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-1209.
5. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361:32-39.
6. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236: 1011-1019.
7. Schreyogg J, Weller J, Stargardt T, et al. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. J Nucl Med. 2010;51:1668-1675.
8. Koyama H, Ohno Y, Seki S, et al. Magnetic resonance imaging for lung cancer. J Thorac Imaging. 2013;28:138-150.
9. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008; 248:643-654.
10. Yi CA, Lee KS, Lee HY, et al. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: Comparisons of clinical effectiveness in a randomized trial. Cancer. 2013;119: 1784-1791.
11. Yi CA, Shin KM, Lee KS, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248: 632-642.
12. Zaidi H, Montandon ML, Alavi A. The clinical role of fusion imaging using PET, CT, and MR imaging. Magn Reson Imaging Clin N Am. 2010;18:133-149.
13. Herzog H. PET/MRI: challenges, solutions and perspectives. Z Med Phys. 2012;22:281-298.
14. Zaidi H, Del Guerra A. An outlook on future design of hybrid PET/MRI systems. Med Phys. 2011;38:5667-5689.
15. Delso G, Furst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011;52:1914-1922.
16. Wurslin C, Schmidt H, Martirosian P, et al. Respiratory motion correction in oncologic PET using T1-weighted MR imaging on a simultaneous whole-body PET/MR system. J Nucl Med. 2013;54:464-471.
17. Slomka PJ, Baum RP. Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol Imaging. 2009;36(suppl 1):S44-S55.
18. Shan ZY, Mateja SJ, Reddick WE, et al. Retrospective evaluation of PET-MRI registration algorithms. J Digit Imaging. 2011;24:485-493.
19. Hofmann M, Pichler B, Scholkopf B, et al. Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging. 2009; 36(suppl 1):S93-S104.
20. Martinez-Moller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520-526.
21. Schulz V, Torres-Espallardo I, Renisch S, et al. Automatic, three-segment, MR-based attenuation correction for wholebody PET/MR data. Eur J Nucl Med Mol Imaging. 2011;38:138-152.
22. Keereman V, Holen RV, Mollet P, et al. The effect of errors in segmented attenuation maps on PET quantification. Med Phys. 2011;38:6010-6019.
23. Hofmann M, Bezrukov I, Mantlik F, et al. MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation-and atlas-based methods. J Nucl Med. 2011;52:1392-1399.
24. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-855.
25. Schwenzer NF, Schraml C, Muller M, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging-pilot study. Radiology. 2012;264: 551-558.
26. Bailey DL, Barthel H, Beyer T, et al. Summary Report of the First International Workshop on PET/MR Imaging, March 19-23, 2012, Tubingen, Germany. Mol Imaging Biol. 2013; 15:361-371.
27. Brendle CB, Schmidt H, Fleischer S, et al. Simultaneously acquired MR/PET images compared with sequential MR/PET and PET/CT: alignment quality. Radiology. 2013;268: 190-199.
28. Lois C, Bezrukov I, Schmidt H, et al. Effect of MR contrast agents on quantitative accuracy of PET in combined wholebody PET/MR imaging. Eur J Nucl Med Mol Imaging. 2012;39:1756-1766.
29. Hoetjes NJ, van Velden FH, Hoekstra OS, et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging. 2010;37: 1679-1687.
30. Martinez-Moller A, Eiber M, Nekolla SG, et al. Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med. 2012;53: 1415-1426.
31. Zenge MO, Vogt FM, Brauck K, et al. High-resolution continuously acquired peripheral MR angiography featuring partial parallel imaging GRAPPA. Magn Reson Med. 2006; 56:859-865.
32. Kim YN, Yi CA, Lee KS, et al. A proposal for combined MRI and PET/CT interpretation criteria for preoperative nodal staging in non-small-cell lung cancer. Eur Radiol. 2012; 22:1537-1546.
33. Thomson V, Pialat JB, Gay F, et al. Whole-body MRI for metastases screening: a preliminary study using 3D VIBE sequences with automatic subtraction between noncontrast and contrast enhanced images. Am J Clin Oncol. 2008;31: 285-292.
34. Hamm B, Mahfouz AE, Taupitz M, et al. Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology. 1997;202:677-682.
35. Van Dijk P, Sijens PE, Schmitz PI, et al. Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. Magn Reson Imaging. 1997;15:535-541.
36. Smirniotopoulos JG, Murphy FM, Rushing EJ, et al. Patterns of contrast enhancement in the brain and meninges. Radiographics. 2007;27:525-551.
37. Biederer J, Schoene A, Freitag S, et al. Simulated pulmonary nodules implanted in a dedicated porcine chest phantom: sensitivity of MR imaging for detection. Radiology. 2003; 227:475-483.
38. Schroeder T, Ruehm SG, Debatin JF, et al. Detection of pulmonary nodules using a 2D HASTE MR sequence: comparison with MDCT. AJR Am J Roentgenol. 2005; 185:979-984.
39. Frericks BB, Meyer BC, Martus P, et al. MRI of the thorax during whole-body MRI: evaluation of different MR sequences and comparison to thoracic multidetector computed tomography (MDCT). J Magn Reson Imaging. 2008;27: 538-545.
40. Bruegel M, Gaa J, Woertler K, et al. MRI of the lung: value of different turbo spin-echo, single-shot turbo spin-echo, and 3D gradient-echo pulse sequences for the detection of pulmonary metastases. J Magn Reson Imaging. 2007; 25:73-81.
41. Chandarana H, Heacock L, Rakheja R, et al. Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging. Radiology. 2013; 268:874-881.
42. Siegel MJ, Acharyya S, Hoffer FA, et al. Whole-body MR imaging for staging of malignant tumors in pediatric patients: results of the American College of Radiology Imaging Network 6660 Trial. Radiology. 2013;266: 599-609.
43. Choi SH, Kim YT, Kim SK, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg. 2011;92:1826-1832.
44. Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology. 2000;216:117-121.
45. Chun EJ, Lee HJ, Kang WJ, et al. Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: the feasibility of integrated (18)F-FDG PET/CT. Lung Cancer. 2009;65:180-186.
46. UyBico SJ, Wu CC, Suh RD, et al. Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics. 2010;30:1163-1181.
47. Padovani B, Mouroux J, Seksik L, et al. Chest wall invasion by bronchogenic carcinoma: evaluation with MR imaging. Radiology. 1993;187:33-38.
48. Sakai S, Murayama S, Murakami J, et al. Bronchogenic carcinoma invasion of the chest wall: evaluation with dynamic cine MRI during breathing. J Comput Assist Tomogr. 1997; 21:595-600.
49. Ohno Y, Adachi S, Motoyama A, et al. Multiphase ECGtriggered 3D contrast-enhanced MR angiography: utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. J Magn Reson Imaging. 2001;13:215-224.
50. Lee CH, Goo JM, Kim YT, et al. The clinical feasibility of using non-breath-hold real-time MR-echo imaging for the evaluation of mediastinal and chest wall tumor invasion. Korean J Radiol. 2010;11:37-45.
51. Plathow C, Aschoff P, Lichy MP, et al. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer-initial results. Invest Radiol. 2008; 43:290-297.
52. Kim HY, Yi CA, Lee KS, et al. Nodal metastasis in non-small cell lung cancer: accuracy of 3.0-T MR imaging. Radiology. 2008;246:596-604.
53. Ohno Y, Koyama H, Nogami M, et al. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. J Magn Reson Imaging. 2007;26:1071-1080.
54. Ohno Y, Hatabu H, Takenaka D, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology. 2004;231: 872-879.
55. Ohno Y, Koyama H, Yoshikawa T, et al. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Radiology. 2011;261:605-615.
56. Nomori H, Mori T, Ikeda K, et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg. 2008;135:816-822.
57. Buchbender C, Heusner TA, Lauenstein TC, et al. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53: 928-938.
58. Schmidt GP, Baur-Melnyk A, Tiling R, et al. Comparison of high resolution whole-body MRI using parallel imaging and PET-CT. First experiences with a 32-channel MRI system. Radiologe. 2004;44:889-898.
59. Rohren EM, Provenzale JM, Barboriak DP, et al. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology. 2003;226:181-187.
60. Schmidt GP, Baur-Melnyk A, Herzog P, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol. 2005;40:743-753.
61. Lee HY, Lee KS, Kim BT, et al. Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. J Korean Med Sci. 2009;24:1132-1138.
62. Donati OF, Hany TF, Reiner CS, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med. 2010;51: 692-699.
63. Ohno Y, Nogami M, Higashino T, et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J Magn Reson Imaging. 2005;21: 775-783.
64. Chang YC, Yu CJ, Chen CM, et al. Dynamic contrastenhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging. 2012;36:387-396.
65. Yabuuchi H, Hatakenaka M, Takayama K, et al. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology. 2011;261:598-604.
66. Chang Q, Wu N, Ouyang H, et al. Diffusion-weighted magnetic resonance imaging of lung cancer at 3.0 T: a preliminary study on monitoring diffusion changes during chemoradiation therapy. Clin Imaging. 2012;36:98-103.
67. Ohno Y, Koyama H, Yoshikawa T, et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. Am J Roentgenol. 2012;198:75-82.
68. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657.
69. Lee DH, Kim SK, Lee HY, et al. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol. 2009;4:816-821.
70. Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol. 2013;14:1-12.
71. Ahmed BA, Connolly BL, Shroff P, et al. Cumulative effective doses from radiologic procedures for pediatric oncology patients. Pediatrics. 2010;126:e851-e858.
72. Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680 000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ. 2013;346:f2360.
73. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380:499-505.
74. Hirsch FW, Sattler B, Sorge I, et al. PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol. 2013;43:860-875.
75. Torigian DA, Zaidi H, Kwee TC, et al. PET/MR imaging: technical aspects and potential clinical applications. Radiology. 2013;267:26-44.
76. Presant CA, Wolf W, Waluch V, et al. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet. 1994;343:1184-1187.
77. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 2010;256:348-364.
78. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 2010;20:1456-1467.
79. Cho H, Ackerstaff E, Carlin S, et al. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia. 2009;11:247-259.
80. Mankoff DA, Dunnwald LK, Partridge SC, et al. Blood flowmetabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res. 2009;15:5294-5296.
81. Horsman MR, Mortensen LS, Petersen JB, et al. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9:674-687.